OSCR
Oscar Health, Inc.
OSCR has the edge over VVOS overall, supported by stronger fundamentals and lower modeled downside.
VVOS
Vivos Therapeutics, Inc.
VVOS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VVOS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VVOS's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VVOS PE Valuation
VVOS has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VVOS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect VVOS's losses to grow, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus VVOS down 117%.
VVOS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$10.12 | +$2.88 |
| Q2 2024 | -$11.47 | +$6.28 |
| Q1 2024 | -$15.37 | +$6.13 |
| Q4 2023 | -$15.49 | +$10.51 |
| Q3 2023 | -$13.00 | +$16.00 |
| Q2 2023 | -$17.75 | +$11.25 |
| Q1 2023 | -$21.50 | +$4.00 |
| Q4 2022 | -$26.00 | -$2.00 |
VVOS is still losing money, but far less than before: $1.90 per share over the past year, against $29.00 at its worst in mid-2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over VVOS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VVOS on profitability, with a higher operating margin.
VVOS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5.2M | +35% |
| Q1 2026 | $5.1M | +70% |
| Q4 2025 | $3.8M | +3.4% |
| Q3 2025 | $6.8M | +76% |
| Q2 2025 | $3.8M | -5.8% |
| Q1 2025 | $3M | -12% |
| Q4 2024 | $3.7M | +14% |
| Q3 2024 | $3.9M | +17% |
VVOS's revenue has grown year over year for four quarters in a row: $5M last quarter, up 35% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | +34 points |
| Q1 2026 | -129% | +1.2 points |
| Q4 2025 | -167% | -91 points |
| Q3 2025 | -70% | -1.3 points |
| Q2 2025 | -127% | -80 points |
| Q1 2025 | -130% | -19 points |
| Q4 2024 | -76% | +56 points |
| Q3 2024 | -69% | +37 points |
VVOS's operating margin was −94% last quarter, up 34 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VVOS on cash generation, producing positive trailing cash flow while its opponent burns cash.
VVOS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$3.6M | +$701K |
| Q1 2026 | -$6M | -$2.1M |
| Q4 2025 | -$5.3M | -$2.2M |
| Q3 2025 | -$4.1M | +$301K |
| Q2 2025 | -$4.3M | -$1.2M |
| Q1 2025 | -$3.9M | -$1.3M |
| Q4 2024 | -$3.1M | -$192K |
| Q3 2024 | -$4.4M | -$1.4M |
VVOS has burned cash in almost every quarter: −$19M over the past year, against −$16M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over VVOS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
VVOS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +3M shares |
| 1 year | +106% | +9.1M shares |
| 3 years | +1982% | +16.8M shares |
| 5 years | +3457% | +17.2M shares |
VVOS has 18M diluted shares, up 106% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2M |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | $150,000 |
| Q4 2019 | — |
| Q3 2019 | $50,000 |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VVOS Net Leverage
VVOS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VVOS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.8 | Oversold |
| Stochastic | 1.3 | Oversold |
VVOS's weekly RSI is 23 (oversold) and its Stochastic is 1 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VVOS PE vs Healthcare Sector
VVOS has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VVOS on trend strength, trading above more of its moving averages.
VVOS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.13 | 23% below |
| 20 week MA | $0.24 | 58% below |
| 50 week MA | $0.88 | 89% below |
| 100 week MA | $2.22 | 95% below |
| 200 week MA | $4.63 | 98% below |
VVOS is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VVOS on returns for 2026, with the stronger performance.
VVOS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $224.8 | $184.5 | -18% |
| 2021 | $184.5 | $68.5 | -63% |
| 2022 | $68.5 | $11.9 | -83% |
| 2023 | $11.9 | $12.4 | +4.3% |
| 2024 | $12.4 | $4.65 | -63% |
| 2025 | $4.65 | $2.03 | -56% |
| 2026 YTD | $2.03 | $0.10 | -95% |
VVOS has finished lower in five of the last six years. It's down 95% so far in 2026.